SRT did not improve survival over whole-brain radiotherapy after matching in SCLC
After propensity matching, SRT did not improve survival over WBRT, while adding a boost showed a non-robust intracranial control signal.
After propensity matching, SRT did not improve survival over WBRT, while adding a boost showed a non-robust intracranial control signal.
Among patients under 70, twice-daily chemoradiotherapy was associated with 36.0 versus 22.2 months median survival, without higher acute toxicity.
TREASURE found no survival benefit and higher serious toxicity with thoracic radiotherapy added to atezolizumab maintenance.